MarketCap
Actinium Pharmaceuticals ATNM
$ 1.42
8.4%
Facebook
X
Telegram
Actinium Pharmaceuticals ROE Ratio | ATNM
Annual ROE Ratio Actinium Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -432.56 | -116.74 | -134.19 | -49.66 | -33.69 | -36.23 | -387.97 | -268.4 | -194.58 | -135.06 | -95.68 | 1284.12 | 690.83 | -729.83 | - | -117.09 | -405.36 | -133.96 | -162.36 | -331.92 | -6166.59 | -1305.96 | -224.41 | 190.56 | 293.76 | -60.69 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1284.12 | -6166.59 | -362.55 |
Quarterly ROE Ratio Actinium Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -220.99 | -375.1 | -165.71 | -154.38 | -137.97 | -75.94 | -106.41 | -104.73 | -98.12 | -78.36 | -91.65 | -71.13 | -49.97 | -30.68 | -38.68 | -31.62 | -29.21 | -21.76 | -30.79 | -30.34 | -33.34 | -25.82 | -142.74 | -222.78 | -315.7 | -306.45 | -376.21 | -314.47 | -297.15 | -196.69 | -242.94 | -224.78 | -228.57 | -156.81 | -193.46 | -183.99 | -156.85 | -97.88 | -115.84 | -113.16 | -90.37 | -65.92 | 250.18 | 85.3 | 987.89 | 1001.88 | 1092.99 | 955.41 | 1182.43 | 313.81 | 50.86 | -176.65 | -1085.0 | -1129.18 | -1129.58 | -862.46 | -745.58 | -0.4 | 4.17 | -19.51 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1182.43 | -1129.58 | -87.82 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
269.84 | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-185.29 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.91 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
88.41 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-33.23 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-68.38 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-97.66 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
-55.54 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-32.07 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
3.84 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
7.08 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-8.68 | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
32.87 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
36.21 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-36.97 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
37.48 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
2.47 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-109.81 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-195.54 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-172.78 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
32.87 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-192.87 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-142.61 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-400.07 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-54.92 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-107.78 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-20.16 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-222.05 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-17.1 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-7.42 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-597.64 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-15.82 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-87.03 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
-11.49 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
28.85 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
-1949.71 | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
34.7 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.58 | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-29.5 | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
-138.81 | $ 0.88 | 3.67 % | $ 11.6 M | USA |